Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.59 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.59 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ESRRB | O95718 | 1/20 | 0.50 |
| ▸ | ESRRG | P62508 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38660041 | 0.95 | LMNA (0.68) | LMNASMN1; SMN2MAPTCYP4F2CYP4A11 | |
| SCHEMBL19888143 | 0.90 | LMNA (0.63) | LMNASMN1; SMN2MAPTCYP4F2CYP4A11 | |
| SCHEMBL2060889 | 0.89 | SMN1; SMN2 (0.60) | LMNASMN1; SMN2MAPTCYP4F2CYP4A11 | |
| SCHEMBL4113212 | 0.85 | CYP4F2 (0.76) | LMNASMN1; SMN2MAPTCYP4F2CYP4A11 | |
| SCHEMBL23582754 | 0.84 | SMN1; SMN2 (0.56) | LMNASMN1; SMN2MAPTCYP4F2CYP4A11 | |
| SCHEMBL5697620 | 0.83 | SMN1; SMN2 (0.55) | LMNASMN1; SMN2MAPTNR1H4EPHX2 | |
| SCHEMBL841124 | 0.83 | CYP4F2 (0.58) | LMNASMN1; SMN2MAPTCYP4F2CYP4A11 | |
| SCHEMBL1759388 | 0.83 | CYP4F2 (0.58) | LMNASMN1; SMN2MAPTCYP4F2CYP4A11 | |
| SCHEMBL10582742 | 0.81 | SMN1; SMN2 (0.54) | LMNASMN1; SMN2MAPTNR1H4EPHX2 | |
| SCHEMBL2008590 | 0.81 | NR1H4 (0.54) | LMNASMN1; SMN2MAPTCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 467 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260013536-A1 | FLAVOR COMPOSITION AND FOOD OR BEVERAGE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2026-01-15 | — | — | US | claimed |
| EP-4563008-A1 | FRAGRANCE COMPOSITION AND FOOD OR BEVERAGE | Takasago International Corporation (JP) | 2025-06-04 | — | — | EP | claimed |
| CN-119584869-A | Perfume composition and food and beverage | 高砂香料工业株式会社 | 2025-03-07 | — | — | CN | claimed |
| US-20240306688-A1 | METHOD OF MITIGATING OFF-ODORS | GIVAUDAN SA (CH) | 2024-09-19 | — | — | US | claimed |
| EP-4391827-A1 | METHOD OF MITIGATING OFF-ODORS | Givaudan SA (CH) | 2024-07-03 | — | — | EP | claimed |
| CN-117897055-A | Method for reducing abnormal odor | 奇华顿股份有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-117164593-A | Pyrimidoindoles compound, preparation method and application thereof, and anti-erythroleukemia drug | 贵州省天然产物研究中心 | 2023-12-05 | — | — | CN | claimed |
| CN-115974688-A | Synthesis method of p-tert-butyl methyl phenylacetate | 滕州市悟通香料有限责任公司 | 2023-04-18 | — | — | CN | claimed |
| WO-2023025549-A1 | METHOD OF MITIGATING OFF-ODORS | GIVAUDAN SA (CH) | 2023-03-02 | — | — | WO | claimed |
| CN-113831240-A | Production method of methyl p-tert-butyl phenylacetate | 滕州市天水生物科技有限公司 | 2021-12-24 | — | — | CN | claimed |
| JP-4739231-B2 | — | — | 2011-08-03 | — | — | JP | claimed |
| EP-1716159-B1 | BICYCLIC SILOXANE COMPOSITIONS FOR THE RELEASE OF ACTIVE INGREDIENTS | MOMENTIVE PERFORMANCE MAT INC (US) | 2011-07-13 | — | — | EP | claimed |
| US-7579495-B2 | Active-releasing cyclic siloxanes | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2009-08-25 | — | — | US | claimed |
| US-7576170-B2 | Cyclic siloxane compositions for the release of active ingredients | MOMENTIVE PERFORMANCE MATERIALS (US) | 2009-08-18 | — | — | US | claimed |
| EP-1697386-B1 | ACTIVE INGREDIENT-RELEASING CYCLIC SILOXANES | GEN ELECTRIC (US) | 2007-10-10 | — | — | EP | claimed |
| CN-1944390-A | Process for preparing P-tertiary butyl phenyl acetic ester organic compounds | UNIV SHANGHAI (CN) | 2007-04-11 | — | — | CN | claimed |
| EP-1697386-A1 | ACTIVE INGREDIENT-RELEASING CYCLIC SILOXANES | General Electric Company A Corporation of the State of New York (US) | 2006-09-06 | — | — | EP | claimed |
| WO-2005066187-A1 | ACTIVE INGREDIENT-RELEASING CYCLIC SILOXANES | GENERAL ELECTRIC COMPANY (US) | 2005-07-21 | — | — | WO | claimed |
| US-20050136021-A1 | Active-releasing cyclic siloxanes | MOMENTIVE PERFORMANCE MATERIALS INC. | 2005-06-23 | — | — | US | claimed |
| US-20050136022-A1 | Cyclic siloxane compositions for the release of active ingredients | MOMENTIVE PERFORMANCE MATERIALS INC. | 2005-06-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050136022-A1 | Cyclic siloxane compositions for the release of active ingredients | F9, RPL39, ECPAS | LMNA 568/4885SMN1; SMN2 769/4885MAPT 815/4885 |
| US-20050136021-A1 | Active-releasing cyclic siloxanes | F9, RPL39, ALDH16A1 | LMNA 882/4885SMN1; SMN2 692/4885MAPT 1453/4885 |
| US-20260013536-A1 | FLAVOR COMPOSITION AND FOOD OR BEVERAGE | EBP, FABP7, FABP2 | LMNA 1010/4885SMN1; SMN2 1883/4885MAPT 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.